Nearly half of the world’s population suffers from scalp-related maladies, and traditionally, these conditions are addressed ...

For breast cancer survivors, we shine a light on a crucial aspect of recovery: the management of wounds and scars ...

The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) ...

Researchers developed the TUS Skin Bacteria Co-culture (TSBC) medium, a novel system that enables the balanced cultivation of ...

Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first anti-TSLP showing clinical proof of concept in atopic dermatitis, which is ...

The average air quality index in Delhi increased to 494 on Tuesday, well beyond the “severe plus” category for air pollution ...

Brown Regular,sans-serif;font-size:.9rem;font-weight:300;line-height:1.3em;color:#333;padding:0 0 .4rem;margin:1rem auto;text ...

All hair types can experience oily roots, but fine hair is particularly prone to the hair woe. Here, dermatologists and a ...

BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

Researchers assessed the prevalence of occupational allergic contact dermatitis and characterized common occupational allergens in a cohort of construction workers.

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...